Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences

References

• Amsterdam, J. V., A. Opperhuizen, and W. van den Brink. 2011. Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology 59 (3):423–29. doi:10.1016/j.yrtph.2011.01.006.
   PubMed Web of Science ®Google Scholar
• Anthony, J. E. C., A. Winstock, J. A. Ferris, and D. J. Nutt. 2020. Improved colour blindness symptoms associated with recreational psychedelic use: Results from the global drug survey 2017. Drug Science, Policy and Law 6:205032452094234. doi:10.1177/2050324520942345.
   Google Scholar
• Arnett, J. J. 2007. Emerging adulthood: What is it, and what is it good for? Child Development Perspectives 1 (2):68–73. doi:10.1111/j.1750-8606.2007.00016.x.
   Web of Science ®Google Scholar
• Belouin, S. J., and J. E. Henningfield. 2018. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology 142:7–19. doi:10.1016/j.neuropharm.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Bheatrix, B., N. Stamato Ruschel, M. Luiza Campos, M. Aurélio Negreiros, and D. C. Mograbi. 2020. Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. PloS One 15 (2):e0229067–e0229067. doi:10.1371/journal.pone.0229067.
   PubMed Web of Science ®Google Scholar
• Bøhling, F. 2017. Psychedelic pleasures: An affective understanding of the joys of tripping. The International Journal of Drug Policy 49:133–43. doi:10.1016/j.drugpo.2017.07.017.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., M. Bolstridge, J. Rucker, C. M. J. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, et al. “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.” The Lancet. Psychiatry 3, no. 7 (2016): 619–27. doi:10.1016/S2215-0366(16)30065-7.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., D. Erritzoe, T. Williams, J. M. Stone, L. J. Reed, A. Colasanti, R. J. Tyacke, et al. “Neural correlates of the psychedelic state as determined by fmri studies with psilocybin.” Proceedings of the National Academy of Sciences - PNAS 109, no. 6 (2012a): 2138–43. doi:10.1073/pnas.1119598109.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., R. Leech, T. M. Williams, D. Erritzoe, N. Abbasi, T. Bargiotas, P. Hobden, et al. “Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin.” British Journal of Psychiatry 200, no. 3 (2012b): 238–44. doi:10.1192/bjp.bp.111.103309.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology (Oxford) 32 (7):725–31. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• Caroline, D., J. Palamar, and M. G. Shedlin. 2019. Ceremonial ‘Plant medicine’ use and its relationship to recreational drug use: an exploratory study. Addiction Research & Theory 27 (2):68–75. doi:10.1080/16066359.2018.1455187.
   PubMed Web of Science ®Google Scholar
• Clarke, V., and V. Braun. 2017. Thematic Analysis. The Journal of Positive Psychology 12 (3):297–98. doi:10.1080/17439760.2016.1262613.
   Web of Science ®Google Scholar
• Corbin, M. 2012. Tactics of legitimation in the psychedelic sciences: Lessons for feminist sociology of knowledge. The American Behavioral Scientist (Beverly Hills) 56 (10):1413–33. doi:10.1177/0002764212454422.
   Web of Science ®Google Scholar
• Davis, A. K., and H. Rosenberg. 2014. The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. Journal of Psychoactive Drugs 46 (2):154–61. doi:10.1080/02791072.2014.901586.
   PubMed Web of Science ®Google Scholar
• Dyck, E., and C. Elcock. 2020. Reframing bummer trips: Scientific and cultural explanations to adverse reactions to psychedelic drug use. The Social History of Alcohol and Drugs 34 (2):271–96. doi:10.1086/707512.
   Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford) 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D. Richards, U. McCann, and R. Jesse. 2011. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218 (4):649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Hallock, R. M., A. Dean, Z. A. Knecht, J. Spencer, and E. C. Taverna. 2012. A survey of hallucinogenic mushroom use, Factors related to usage, and perceptions of use among college students. Drug and Alcohol Dependence 130 (1):245–48. doi:10.1016/j.drugalcdep.2012.11.010.
   PubMed Web of Science ®Google Scholar
• Hendricks, P. S., C. B. Thorne, C. Brendan Clark, D. W. Coombs, and M. W. Johnson. 2015. Classic psychedelic use is associated with reduced psychological distress and suicidality in the united states adult population. Journal of Psychopharmacology (Oxford) 29 (3):280–88. doi:10.1177/0269881114565653.
   PubMed Web of Science ®Google Scholar
• Honyiglo, E., A. Franchi, N. Cartiser, C. Bottinelli, A. Advenier, F. Bévalot, and L. Fanton. 2019. Unpredictable behavior under the influence of “Magic Mushrooms”: A case report and review of the literature. Journal of Forensic Sciences 64 (4):1266–70. doi:10.1111/1556-4029.13982.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, P. S. Johnson, and R. R. Griffiths. 2017. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology (Oxford) 31 (7):841–50. doi:10.1177/0269881116684335.
   PubMed Web of Science ®Google Scholar
• Jones, L., P. Reed, and A. Parrott. 2016. Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users. Journal of Psychopharmacology (Oxford) 30 (12):1313–20. doi:10.1177/0269881116653106.
   PubMed Web of Science ®Google Scholar
• Krebs, T. S., and P.-Ø. Johansen. 2013. Over 30 million psychedelic users in the United States. F1000 Research 2:98–98. doi:10.12688/f1000research.2-98.v1.
   PubMedGoogle Scholar
• Lancelotta, R. L., and A. K. Davis. 2020. Use of benefit enhancement strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) users: Associations with mystical, challenging, and enduring effects. Journal of Psychoactive Drugs 52 (3):273–81. doi:10.1080/02791072.2020.1737763.
   PubMed Web of Science ®Google Scholar
• Lea, T., N. Amada, and H. Jungaberle. 2020. Psychedelic microdosing: a subreddit analysis. Journal of Psychoactive Drugs 52 (2):101–12. doi:10.1080/02791072.2019.1683260.
   PubMed Web of Science ®Google Scholar
• Leonard, J. B., B. Anderson, and W. Klein-Schwartz. 2018. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Journal of Psychopharmacology (Oxford) 32 (12):1286–94. doi:10.1177/0269881118793086.
   PubMed Web of Science ®Google Scholar
• Lincoln, Y. S., and E. G. Guba. 1985. Naturalistic Inquiry. Newbury Park, CA: SAGE.
   Google Scholar
• Luoma, J. B., C. Chwyl, G. J. Bathje, A. K. Davis, and R. Lancelotta. 2020. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs 52 (4):289–99. doi:10.1080/02791072.2020.1769878.
   PubMed Web of Science ®Google Scholar
• Mason, N. L., E. Mischler, M. V. Uthaug, and K. P. C. Kuypers. 2019. Sub-Acute effects of psilocybin on empathy, creative thinking, and subjective well-being. Journal of Psychoactive Drugs 51 (2):123–34. doi:10.1080/02791072.2019.1580804.
   PubMed Web of Science ®Google Scholar
• Móró, L., K. Simon, I. Bárd, and J. Rácz. 2011. Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. Journal of Psychoactive Drugs 43 (3):188–98. doi:10.1080/02791072.2011.605661.
   PubMed Web of Science ®Google Scholar
• Muttoni, S., M. Ardissino, and C. John. 2019. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders 258:11–24. doi:10.1016/j.jad.2019.07.076.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. 2004. Hallucinogens. Pharmacology & Therapeutics (Oxford) 101 (2):131–81.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E., M. W. Johnson, and C. D. Nichols. 2017. Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology and Therapeutics 101 (2):209–19. doi:10.1002/cpt.557.
   PubMed Web of Science ®Google Scholar
• Palamar, J. J., and P. Acosta. 2020. A qualitative descriptive analysis of effects of Psychedelic Phenethylamines And Tryptamines. Human Psychopharmacology 35 (1):e2719–n/a. doi:10.1002/hup.2719.
   PubMed Web of Science ®Google Scholar
• Parker, H. J., J. Aldridge, and F. Measham. 1998. Illegal leisure: The normalization of adolescent recreational drug use. London; New York: Routledge.
   Google Scholar
• Pestana, J., F. Beccaria, and E. Petrilli. 2021. Psychedelic substance use in the reddit Psychonaut community. A qualitative study on motives and modalities. Drugs and Alcohol Today 21 (2):112–23. doi:10.1108/DAT-03-2020-0016.
   Web of Science ®Google Scholar
• Petri, G., P. Expert, F. Turkheimer, R. Carhart-Harris, D. Nutt, P. J. Hellyer, and F. Vaccarino. 2014. Homological Scaffolds of brain functional networks. Journal of the Royal Society Interface 11 (101):20140873–20140873. doi:10.1098/rsif.2014.0873.
   PubMed Web of Science ®Google Scholar
• Riley, S. C. E., and G. Blackman. 2008. Between prohibitions: patterns and meanings of magic mushroom use in the UK. Substance Use & Misuse 43 (1):55–71. doi:10.1080/10826080701772363.
   PubMed Web of Science ®Google Scholar
• Riley, S., J. Thompson, and C. Griffin. 2010. Turn on, Tune in, but don’t drop out: The Impact of Neo-Liberalism on magic mushroom users’ (in)ability to imagine collectivist social worlds. The International Journal of Drug Policy 21 (6):445–51. doi:10.1016/j.drugpo.2010.07.001.
   PubMed Web of Science ®Google Scholar
• Roberts, C. A., I. Osborne-Miller, J. Cole, S. H. Gage, and P. Christiansen. 2020. Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use. Journal of Psychopharmacology (Oxford) 34 (9):999–1007. doi:10.1177/0269881120936508.
   PubMed Web of Science ®Google Scholar
• Ruane, D. 2015. harm reduction or psychedelic support? Caring for drug-related crises at transformational festivals. Dancecult 7 (1):55–75. doi:10.12801/1947-5403.2015.07.01.03.
   Google Scholar
• Sessa, Ben. 2014. Why psychiatry needs psychedelics and psychedelics need psychiatry. Journal of psychoactive drugs 46 (1): 57–62.
   PubMed Web of Science ®Google Scholar
• Sexton, J. D., M. S. Crawford, N. W. Sweat, A. Varley, E. E. Green, and P. S. Hendricks. 2019. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Journal of Psychopharmacology (Oxford) 33 (9):1058–67. doi:10.1177/0269881119827796.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. 2017. “Canadian tobacco alcohol and drugs (CTADS): 2015 summary.” Last modified June 27, 2017. https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2015-summary.html
   Google Scholar
• Uthaug, M. V., R. Lancelotta, A. Szabo, A. K. Davis, J. Riba, and J. G. Ramaekers. 2020. Prospective examination of synthetic 5-Methoxy-N,N-Dimethyltryptamine Inhalation: Effects on Salivary IL-6, Cortisol levels, affect, and non-judgment. Psychopharmacology 237 (3):773–85. doi:10.1007/s00213-019-05414-w.
   PubMed Web of Science ®Google Scholar
• Wark, C., and J. F. Galliher. 2009. Timothy leary, richard alpert (ram dass) and the changing definition of psilocybin. The International Journal of Drug Policy 21 (3):234–39. doi:10.1016/j.drugpo.2009.08.004.
   PubMed Web of Science ®Google Scholar